ClinicalTrials.gg
RecruitingNCT07549919Updated Apr 24, 2026

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

A Phase 1 interventional study of AJ201 in Healthy Male Adults and Food Effect in Healthy Volunteers, sponsored by AnnJi Pharmaceutical Co., Ltd.. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by AnnJi Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a Phase 1, randomized, single-dose, open-label, two-way crossover study to evaluate the effect of food on AJ201, and to evaluate the safety, tolerability, and pharmacokinetics of AJ201 in Japanese and White healthy male participants.

02

Conditions studied

  • Healthy Male Adults
  • Food Effect in Healthy Volunteers

Keywords

  • Healthy Male Adults
  • Healthy Volunteers
  • Food Effect
03

In context

Lead sponsor

AnnJi Pharmaceutical Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Male, non-smokers (no use of tobacco or nicotine products within 3 months prior to Screening), ≥ 18 and ≤ 55 years of age, with (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 and body weight ≥ 50.0 kg.
  • Normal renal function at Screening.
  • Healthy as defined by:

    • The absence of illness and surgery within 4 weeks prior to study drug administration.
    • The absence of a clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, depression, attempted suicide, gastrointestinal, renal, hepatic, and metabolic disease.
  • Participants must be either Japanese or White.
  • Able to understand the study procedures and provide signed to participate in the study.

Key Exclusion Criteria:

  • Any clinically significant abnormal finding at physical examination.
  • Clinically significant abnormal laboratory test results or positive serology test results for surface antigen (HBsAg), virus (HCV) antibody, or (HIV) antigen and antibody, at Screening.
  • Positive urine drug screen, urine cotinine test, or alcohol breath test.
  • History of significant allergic reactions to any drug.
  • Clinically significant abnormalities or vital signs abnormalities at Screening.
  • History of drug abuse of any soft drugs or hard drugs.
  • History of alcohol abuse.
  • History of smoking or uses other nicotine-containing products.
  • Undergone major surgery ≤ 3 months before first study drug administration.
  • History of clinically significant opportunistic infection or serious local infection or significant medical/surgical procedure or trauma or any current infection.
  • Use of medications for the timeframes specified in the protocol.
  • Presence of orthodontic braces or orthodontic retention wires, or any physical findings in the mouth or tongue that would interfere with the dosing procedure.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Arm A (Japanese)

    Japanese Participants

    Drug: AJ201

  • Experimental
    Arm B (White)

    White Participants

    Drug: AJ201

Interventions

  • DrugAJ201

    All participants are planned to be administered a single dose of AJ201 for each period (fed and fasted).

06

What researchers measure

Primary outcomes

  1. Plasma PK of AJ201

    AUC0-24hr: Area under the concentration-time curve from zero to 24 hours under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  2. Plasma PK of AJ201

    AUC0-last: Area under the concentration-time curve from zero to the last observed concentration under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  3. Plasma PK of AJ201

    AUC0-inf: Area under the concentration-time curve from time zero to infinity (extrapolated) under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  4. Plasma PK of AJ201

    Cmax: Maximal observed concentration under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  5. Plasma PK of AJ201

    Tmax: Time when the maximal concentration is observed under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  6. Plasma PK of AJ201

    Residual area: Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity, calculated as \[1 - (AUC0-last/AUC0-inf)\] x 100 under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  7. Plasma PK of AJ201

    Tlag: Time of observation prior to the first observation with a measurable (non-zero) concentration under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  8. Plasma PK of AJ201

    T½ el: Terminal elimination half-life under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  9. Plasma PK of AJ201

    Kel: Terminal elimination rate constant under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  10. Plasma PK of AJ201

    Cl/F: Apparent clearance under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  11. Plasma PK of AJ201

    Vz/F: Apparent volume of distribution under fasting and fed conditions

    Time frame: Pre-dose to Day 6

  12. Urine PK of AJ201

    Ae0-24hr: Cumulative urinary excretion from time zero to 24 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

    Time frame: Pre-dose to Day 7

  13. Urine PK of AJ201

    Ae0-48hr: Cumulative urinary excretion from time zero to 48 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

    Time frame: Pre-dose to Day 7

  14. Urine PK of AJ201

    Ae0-last: Cumulative urinary excretion from time zero to the last observed concentrations, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

    Time frame: Pre-dose to Day 7

  15. Urine PK of AJ201

    Rmax: Maximal rate of urinary excretion, calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected under fasting and fed conditions

    Time frame: Pre-dose to Day 7

  16. Urine PK of AJ201

    TRmax: Time of maximal urinary excretion, calculated as the midpoint of the collection interval during which Rmax occurred under fasting and fed conditions

    Time frame: Pre-dose to Day 7

  17. Urine PK of AJ201

    ClR: Renal clearance, calculated as Ae0-24hr /AUC0-24hr under fasting and fed conditions

    Time frame: Pre-dose to Day 7

Secondary outcomes

  1. Safety and Tolerability of AJ201

    Incidence and proportion of volunteers with AEs, including TEAEs and SAEs

    Time frame: Baseline to Day 12

07

Study locations

1 of 1 sites recruiting
  • AnnJi Investigational Site
    Los Alamitos, California 90720, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2026, 0 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Apr 24, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Apr 22, 2026
CompletionEst.
Apr 27, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07549919
Lead sponsor
AnnJi Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Apr 9, 2026
Primary completion
Apr 22, 2026 (estimated)
Completion
Apr 27, 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

Andy Chen, PhD
Contact
andy.chen@ajpharm.com
+886223655677 ext. 801

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion